Janus Henderson Group PLC Cytom X Therapeutics, Inc. Transaction History
Janus Henderson Group PLC
- $187 Billion
- Q3 2024
A detailed history of Janus Henderson Group PLC transactions in Cytom X Therapeutics, Inc. stock. As of the latest transaction made, Janus Henderson Group PLC holds 4,809,518 shares of CTMX stock, worth $5.24 Million. This represents 0.0% of its overall portfolio holdings.
Number of Shares
4,809,518
Previous 6,301,983
23.68%
Holding current value
$5.24 Million
Previous $7.69 Million
26.18%
% of portfolio
0.0%
Previous 0.0%
Shares
4 transactions
Others Institutions Holding CTMX
# of Institutions
71Shares Held
50.7MCall Options Held
112KPut Options Held
8.3K-
Tang Capital Management LLC San Diego, CA7.81MShares$8.51 Million0.79% of portfolio
-
Bvf Inc San Francisco, CA5.23MShares$5.7 Million0.2% of portfolio
-
Vanguard Group Inc Valley Forge, PA5.16MShares$5.63 Million0.0% of portfolio
-
Acadian Asset Management LLC Boston, MA3.1MShares$3.38 Million0.01% of portfolio
-
Prosight Management, LP Dallas, TX3.02MShares$3.29 Million0.96% of portfolio
About CytomX Therapeutics, Inc.
- Ticker CTMX
- Exchange NASDAQ
- Sector Healthcare
- Industry Biotechnology
- Shares Outstandng 65,950,200
- Market Cap $71.9M
- Description
- CytomX Therapeutics, Inc. operates as an oncology-focused biopharmaceutical company in the United States. The company develops antibody therapeutics based on its Probody technology platform for the treatment of cancer. The company's product candidates include CX-2009, an antibody drug conjugates (ADC) against CD166, which is in Phase II clinical...